Papers of interest

Reimbursement models to tackle market failures for antimicrobials: Approaches taken in France, Germany, Sweden, the United Kingdom, and the United States
Dzintars Gotham et al, Health Policy, November 2020 (Open Access)
Precarious antibiotics supply situation: Will the Covid19 Pandemic change anything? (translation D–>E)
Beyer P,, Swiss medical Forum 47-48: 701-705 (November 2020) (Open Access)
Financing Pull Mechanisms for Antibiotic-Related Innovation: Opportunities for Europe
A look at four potential financing models with an evaluation from a European perspective
Årdal C, Lacotte Y, and Ploy MC (EU-JAMRAI), Clin. Infect. Dis. 71: 1994 (2020)
No money for new drugs
Despite an overwhelming global need for pharmaceutical companies to develop more antibiotics, there’s little financial incentive to encourage them
Benjamin Plackett, Nature 586, 22 October 2020
Industry incentives and antibiotic resistance: an introduction to the antibiotic susceptibility bonus
Morel CM, Lindahl O. & al., J. Antibiotics 73: 421-428 (2020)
Needs assessment for novel Gram-negative antibiotics in US hospitals: a retrospective cohort study
Strich J.R. & al., Lancet Inf. Dis.: June 4 (2020)
Antibiotic development — economic, regulatory and societal challenges
Årdal C., Balasegaram M. & al., Nature Rev. Microbiol. 18: 267 (2020)
The global preclinical antibacterialpipeline
Theuretzbacher U., Outterson K. & al., Nature Rev. Microbiol. 18: 275(2020)
Priority pathogens and the antibiotic pipeline: an update
Beyer P. & Paulin S., Bull. WHO 90: 151 (2020)
Biological Risks in Switzerland: Antibiotic resistances
The Swiss Expert Committee for Biosafety SECB produced has a document for biological risks related to Antibiotic Resistance (November 2019)
The Lancet Infectious Diseases Commission on antimicrobial resistance: 6 years later
Description of the state of antimicrobial resistance worldwide 6 years after the first report
A paper from Lancet Infectious Diseases, 11 February 2020
Crisis Looms in Antibiotics as Drug Makers Go Bankrupt
First Big Pharma fled the field, and now start-ups are going belly up, threatening to stifle the development of new drugs
A paper from the New York Times (26.12.2019)
CAESAR annual report 2018
WHO Central Asian and Eastern European Surveillance of Antimicrobial Resistance report containing the Swiss data (from Anresis.ch), November 2019
Swiss Antibiotic Resistance Report 2018
Anresis.ch, ARCH-Vet; November 2019
Incentivising a sustainable response to the threat of AMR
BEAM Alliance, November 2019
Chimeric peptidomimetic antibiotics against Gram-negative bacteria
Luther A., Urfer M., et al., Nature, 23 October 2019

Transferrable Market Exclusivity Extensions to Promote Antibiotic Development: An Economic Analy sis
Benjamin N. R. & al., Clin. Infect. Dis., Open accepted manuscript (20 October 2019)